Author/Authors :
Motlagh, Ali National Cancer Control Secretariat - Ministry of Health and Medical Education - Tehran - Iran , Yamrali, Maisa Department of Radiation Oncology - Iran University of Medical Sciences - Tehran - Iran , Azghandi, Samira Department of Hematology Oncology - Tehran University of Medical Sciences - Tehran - Iran , Azadeh, Payam Department of Radiation Oncology - Shaheed Beheshti Medical University - Tehran - Iran , Vaezi, Mohammad Department of Hematology Oncology - Tehran University of Medical Sciences - Tehran - Iran , Ashrafi, Farzaneh Department of Hematology Oncology - Isfahan University of Medical Sciences - Isfahan - Iran , Zendehdel, Kazem Cancer Research Center - Cancer Institute of Iran - Tehran University of Medical Sciences - Tehran - Iran , Mirzaei, Hamidreza Department of Radiation Oncology - Shaheed Beheshti Medical University - Tehran - Iran , Basi, Ali Department of Hematology Oncology - Iran University of Medical Sciences - Tehran - Iran , Rakhsha, Afshin Department of Radiation Oncology - Shaheed Beheshti Medical University - Tehran - Iran , Seifi, Sharareh Department of Hematology Oncology - Shaheed Beheshti Medical University - Tehran - Iran , Tabatabaeefar, Morteza Department of Radiation Oncology - Shaheed Beheshti Medical University - Tehran - Iran , Elahi, Ahmad Department of Surgery - Alborz University of Medical Sciences - Karaj - Iran , Pirjani, Pouneh Ala Cancer Prevention and Control Center (MACSA) - Tehran - Iran , Moadab Shoar, Leila Department of Radiation Oncology - Iran University of Medical Sciences - Tehran - Iran , Nadarkhani, Faranak Standard and Clinical Guidelines Department - Ministry of Health and Medical Education - Tehran - Iran , Khoshabi, Mostafa Department of Geospatial Information System (GIS) - Center of Excellence in GIS - K.N. Toosi Uni. of Technology - Tehran - Iran , Bahar, Massih Behnam Daheshpour Charity Organization - Tehran - Iran , Esfahani, Fatemeh Iranian Society of Medical Oncology and Hematology - Tehran - Iran , Fudazi, Hossein Iranian Society of Radiation Oncology - Tehran - Iran , Samiei, Farhad Iranian Cancer Association - Tehran - Iran , Farazmand, Borna Department of Radiation Oncology - Mashhad University of Medical Sciences - Ghouchan - Iran , Ahmari, Azin Department of Radiation Oncology - Arak University of Medical Sciences - Arak - Iran , Vand Rajabpour, Mojtaba Cancer Research Center - Cancer Institute of Iran - Tehran University of Medical Sciences - Tehran - Iran , Janbabaei, Ghasem Department of Hematology Oncology - Tehran University of Medical Sciences - Tehran - Iran , Raisi, Alireza Department of Internal Medicine - Shiraz University of Medical Sciences - Shiraz - Iran , Ostovar, Afshin National Cancer Control Secretariat - Ministry of Health and Medical Education - Tehran - Iran , Malekzadeh, Reza National Cancer Control Secretariat - Ministry of Health and Medical Education - Tehran - Iran
Abstract :
On March 11th 2020, the coronavirus outbreak was declared a pandemic by the WHO. One of the groups that is considered high risk in this pandemic are cancer patients as they are treated with a variety of immune system suppressor treatment modalities and this puts them in a great risk for infectious disease (including COVID-19). Therefore, cancer patients require higher level measures for preventing and treating infectious diseases. furthermore, cancer patients may bear additional risk due to the restriction of access to the routine diagnostic and therapeutic services during such epidemic. Since most of the attention of health systems is towards patients affected with COVID-19, the need for structured and unified approaches to COVID-19 prevention and care specific to cancer patients and cancer centers is felt more than ever. This article provides the recommendations and possible actions that should be considered by patients, their caregivers and families, physician, nurses, managers and staff of medical centers involved in cancer diagnosis and treatment. We pursued two major goals in our recommendations: first, limiting the exposure of cancer patients to medical environments and second, modifying the treatment modalities in a manner that reduces the probability of myelosuppression such as delaying elective diagnostic and therapeutic services, shortening the treatment course, or prolonging the interval between treatment courses.
Keywords: